The disclosure relates to the field of immuno-oncology. More specifically, the disclosure relates to methods and compositions for performing single-cell phenotypic and functional analysis of immune and cancer cells disposed within a tumor microenvironment. The methods and compositions permit the determination of whether a subject with a solid tumor is likely to respond to a particular immunomodulator, and also permit the treatment of a solid tumor in a subject by facilitating the selection of an immunomodulator suitable for treating the solid tumor in the subject.

Methods are used for obtaining, cataloguing, and/or storing data derived from a biological source using a flow cell body, electrodes, and an imaging assembly. The data may include DNA and/or RNA obtained from a biological source, such as from the cells of an organism. The methods may be used to obtain, catalog, and/or store data such as DNA or RNA sequence from a pathogen such as a virus and/or a bacteria, human health data over time, and immune system information from an individual. The data obtained using the disclosed methods may be used for a variety of different purposes, including the manufacture of vaccine compositions, and for restoring the immune system of an individual who has undergone an immune system depleting event. The methods may be used for storage of biological cells, which may be used for the screening of compounds, such as small molecules with potential for therapeutic indications.

A method for the evaluation of the efficacy of a drug aiming to eradicate a cellular reservoir of mammalian cells infected with a mammalian immunodeficiency virus, the method including: a) quantifying, the presence of lymphocyte cells expressing a CD32 differentiation marker on their surface; and b) concluding that the drug is efficient to eradicate the cellular reservoir of mammalian cells infected with the mammalian immunodeficiency virus when lymphocyte cells expressing a CD32a differentiation marker are absent.

The invention provides methods for the validation of donor immune-regulatory cells. The validation method includes a combination of assays to determine the capability of immune-regulatory cells to immune-regulate adaptive and innate immune system components.

Provided are methods of determining whether a mammalian subject having an inflammatory condition (e.g., an oral inflammatory condition) will respond positively to mesenchymal stem cell (MSC) therapy, as well as method of treating such inflammatory conditions by administering MSCs.

Devices, methods, and kits are provided for allergy testing based on basophil activation in a blood sample. Susceptibility of an individual to an allergic reaction to an allergen is detected by collecting a blood sample from the individual and assaying for activation of basophils in response to stimulation with an allergen. In particular, a microfluidic device is provided for automating the assay for detecting basophil activation as an indication of the susceptibility of an individual to an allergic reaction as well as kits containing such a device and diagnostic methods for using such a device for allergy testing. Additionally, such a microfluidic device can be adapted for multiplexed detection of allergic responses to multiple allergens by performing assays in parallel to detect the basophil responses to each allergen.

The present application relates to a flow cytometric detection method for lymphocytes in immune cells. The method includes steps of: a) lymphocyte samples stained with immunofluorescent antibodies were added into the pre-cooled PBS-EDTA solution, and the cells were mixed and prepared for flow cytometry detection; b) starting up and warming up a flow cytometer system, adjusting the flow speed, then adding PBS-EDTA solution into a sample tube, and flushing a nozzle system of liquid stream; c) the sample of homogenous cells obtained in step a) is added to the sample tube and then tested. The present detection method can separate cell subpopulations, so that the analysis and detection are more accurate, and is especially suitable for detecting cell subpopulations with small number of cells, thereby saving antibodies and reagents.

Cells comprising an exogenous protein and decreased SH2B adapter protein 3 (SH2B3) protein expression and/or function are provided. Pharmaceutical compositions comprising the cells of the invention as well as methods of treating a disease in a subject in need thereof comprising administering a cell and/or a pharmaceutical composition of the invention, and of determining suitability for treatment, are also provided.

Provided herein are compositions and methods of use relating to a novel class of dendritic cells, referred to herein as ISG+ DC, having anti-tumor activity.

The present invention relates to a method of in vitroprediction of the in vivoefficacy in a patient of treatment with a drug product based on an overall assessment of the properties patients own immune cells when exposed to the drug product with and/0 or without stimulation; the drug product when exposed to said patients own immune cells; and any preexisting antibodies against said drug product in said patient.